t
| Date | 28 Jan 2022 |
| Time | 14:04:43 |
| Category | Holding(s) in company |
| ID | 0266A |
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00BDFBVT43
Issuer Name
OXFORD BIOMEDICA PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An event changing the breakdown of voting
3. Details of person subject to the notification obligation
Name
Novo Holdings A/S
City of registered office (if applicable)
Hellerup
Country of registered office (if applicable)
|
Name |
City of registered office |
Country of registered office |
|
Novo Nordisk Foundation |
Hellerup |
Denmark |
4. Details of the shareholder
|
Name |
City of registered office |
Country of registered office |
|
Novo Holdings A/S |
Hellerup |
Denmark |
5. Date on which the threshold was crossed or reached
01-Jun-2021
6. Date on which Issuer notified
27-Jan-2022
7. Total positions of person(s) subject to the notification obligation
|
|
% of voting rights attached to shares (total of 8.A) |
% of voting rights through financial instruments (total of 8.B 1 + 8.B 2) |
Total of both in % (8.A + 8.B) |
Total number of voting rights held in issuer |
|
Resulting situation on the date on which threshold was |
9.570000 |
0.000000 |
9.570000 |
8253000 |
|
crossed or reached |
|
|
|
|
|
Position of previous notification (if applicable) |
|
|
|
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
|
Class/Type of shares ISIN code(if possible) |
Number of direct voting rights (DTR5.1) |
Number of indirect voting rights (DTR5.2.1) |
% of direct voting rights (DTR5.1) |
% of indirect voting rights (DTR5.2.1) |
|
GB00BDFBVT43 |
8253000 |
0 |
9.570000 |
0.000000 |
|
Sub Total 8.A |
8253000 |
9.570000% |
||
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
|
Type of financial instrument |
Expiration date |
Exercise/conversion period |
Number of voting rights that may be acquired if the instrument is exercised/converted |
% of voting rights |
|
Sub Total 8.B1 |
|
|
|
|
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
|
Type of financial instrument |
Expiration date |
Exercise/conversion period |
Physical or cash settlement |
Number of voting rights |
% of voting rights |
|
Sub Total 8.B2 |
|
|
|
||
9. Information in relation to the person subject to the notification obligation
1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.
|
Ultimate controlling person |
Name of controlled undertaking |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable threshold |
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
The position of Novo Holdings A/S in its previous TR-1 notification was 10.1%. This notification obligation has arisen as a result of issuances of shares by the issuer (and not a disposal of shares by Novo Holdings A/S) and is based upon the latest total voting rights announcement of the issuer dated 4 January 2022.
The qualifying instruments are held by Novo Holdings A/S, the holding company in the Novo Group. Novo Holdings A/S is wholly owned by the Novo Nordisk Foundation.
12. Date of Completion
27-Jan-2022
13. Place Of Completion
London, United Kingdom
|
Contact name: |
Natalie Walter |
|
Contact telephone number: |
01865 783000 |